Immune Pharmaceuticals Receives $2 Million Investment in Common Stock

9/7/16

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of the Company's common stock at a fixed price of$0.50 per share, for gross proceeds of $2,000,000. There are no warrants, no restrictive covenants, and no restrictions on use of proceeds.

For full disclosure, please refer to the Form 8-K filed on September 7, 2016.

About Immune Pharmaceuticals Inc.:

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in Phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and Non-Alcoholic Steato-Hepatitis (NASH), an inflammatory liver disease. Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes Ceplene®/IL-2 approved in Europe and Israel for maintenance remission in Acute Myeloid Leukemia (AML), Azixa® and crolibulin, Phase II-ready vascular disrupting agents, and novel technology platforms; bispecific antibodies and targeted nanotherapeutics, NanomAbs™. Immune's additional pipeline includes AmiKet™ Nano, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharma.com

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.